Utilidad de la plasmaféresis en la pancreatitis aguda por hipertrigliceridemia

A propósito de un caso

  • Reinaldo Andrés Mauricio Rincón Sánchez Fundación Clínica Shaio
  • Gina Sofía Montaño-Padilla Fundación Clínica Shaio
  • Alejandro Concha Mejía Fundación clínica Shaio
  • Karen Damaris Rodríguez Ruíz Fundación Clínica Shaio
Palabras clave: Pancreatitis, hipertrigliceridemia, plasmaféresis.

Resumen

Introducción: la pancreatitis aguda es una entidad de alta incidencia e impacto a nivel mundial. Presenta múltiples causas dentro de las cuales las más frecuentes son la obstrucción de la vía biliar, el consumo de alcohol y, en tercer orden, la hipertrigliceridemia. Esta última se entiende como aquellos niveles séricos de triglicéridos >1000 mg/dL. Dicho escenario representa entre el 1 y el 7 % del total de los casos.

Metodología: presentamos un caso de pancreatitis aguda secundaria a hipertrigliceridemia severa, manejada con plasmaféresis. Se realiza una revisión de la literatura sobre las condiciones, indicaciones y ventajas de esta estrategia terapéutica.

Conclusiones: en casos escogidos, la plasmaféresis es una estrategia de manejo segura y efectiva en el tratamiento de pacientes con pancreatitis aguda secundaria a hipertrigliceridemia severa.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Reinaldo Andrés Mauricio Rincón Sánchez, Fundación Clínica Shaio

Médico internista, especialista en gastroenterología y endoscopia digestiva. Hospital Universitario San Ignacio. Bogotá, Colombia

Gina Sofía Montaño-Padilla, Fundación Clínica Shaio

Residente del programa de medicina crítica y cuidado intensivo de la Universidad de la Sabana, Bogotá, Colombia.

Alejandro Concha Mejía, Fundación clínica Shaio

Gastroenterólogo, internista, epidemiólogo. Residente del programa de medicina crítica y cuidado intensivo de la Universidad de la Sabana. Bogotá, Colombia

Karen Damaris Rodríguez Ruíz, Fundación Clínica Shaio

Médico y cirujano general. Medicina interna.

Referencias bibliográficas

Brisinda G, Vanella S, Crocco A, Mazzari A, Tomaiuolo P, Santullo F, Grossi U, Crucitti A. Severe acute pancreatitis: advances and insights in assessment of severity and management. Eur J Gastroenterol Hepatol. 2011;23(7):541‐551. http://doi.org/10.1097/MEG.0b013e328346e21e

Bae JH, Baek SH, Choi HS, Cho KR, Lee HL, Lee OY, Yoon BC, Hahm JS, Lee MH, Lee DH, Kee CS. Acute pancreatitis due to hypertriglyceridemia: report of 2 cases. Korean J Gastroenterol. 2005;46(6):475‐480.

Whitcomb DC. Genetic aspects of pancreatitis. Annu Rev Med. 2010;61:413‐424.

http://doi.org/10.1146/annurev.med.041608.121416

Fujita K, Maeda N, Kozawa J, Murano K, Okita K, Iwahashi H, Kihara S, Ishigami M, Omura M, Nakamura T, Shirai K, Yamamura T, Funahashi T, Shimomura I. A case of adolescent hyperlipoproteinemia with xanthoma and acute pancreatitis, associated with decreased activities of lipoprotein lipase and hepatic triglyceride lipase. Intern Med. 2010;49(22):2467‐2472.

http://doi.org/10.2169/internalmedicine.49.4058

Dominguez-Muñoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Büchler M, Ditschuneit H. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol. 1991;10(3-4):261‐267.

Olofsson SO, Borèn J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med. 2005;258(5):395‐410.

http://doi.org/10.1111/j.1365-2796.2005.01556.x

Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17(12):3542‐3556.

http://doi.org/10.1161/01.atv.17.12.3542

Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009;296(6):E1183‐E1194. http.//doi.org/10.1152/ajpendo.90899.2008

Criddle DN, Raraty MG, Neoptolemos JP, Tepikin AV, Petersen OH, Sutton R. Ethanol toxicity in pancreatic acinar cells: mediation by nonoxidative fatty acid metabolites. Proc Natl Acad Sci U S A. 2004;101(29):10738‐10743. http://doi.org/10.1073/pnas.0403431101

Sakorafas GH, Tsiotou AG. Etiology and pathogenesis of acute pancreatitis: current concepts. J Clin Gastroenterol. 2000;30(4):343‐356.

http://doi.org/10.1097/00004836-200006000-00002

Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Curr Drug Targets. 2009;10(4):336‐343. http://doi.org/10.2174/138945009787846452

Karabatas L, Oliva ME, Dascal E, Hein GJ, Pastorale C, Chicco A, Lombardo YB, Basabe JC. Is Lipotoxicity presents in the early stages of an experimental model of autoimmune diabetes? Further studies in the multiple low dose of streptozotocin model. Islets. 2010;2(3):190‐199. http://doi.org/10.4161/isl.2.3.11655

Apte MV, Wilson JS. Alcohol-induced pancreatic injury. Best Pract Res Clin Gastroenterol. 2003;17(4):593‐612. http://doi.org/10.1016/s1521-6918(03)00050-7

Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol. 2000;11(8):1067‐1069.

http://doi.org/10.1023/a:1008309613082

Bildirici I, Esinler I, Deren O, Durukan T, Kabay B, Onderoglu L. Hyperlipidemic pancreatitis during pregnancy. Acta Obstet Gynecol Scand. 2002;81(5):468‐470. http://doi.org/10.1034/j.1600-0412.2002.810516.x

Kadikoylu G, Yukselen V, Yavasoglu I, Coşkun A, Karaoglu AO, Bolaman Z. Emergent therapy with therapeutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia. Transfus Apher Sci. 2010;43(3):285‐289.

http://doi.org/10.1016/j.transci.2010.09.009

Lawson EB, Gottschalk M, Schiff DE. Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report. J Pediatr Hematol Oncol. 2011;33(2):e83‐e86.

http://doi.org/10.1097/MPH.0b013e3181f46c22

Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes. 2010;59(3):580‐587.

http://doi.org/10.2337/db09-1297

Mikhail N, Trivedi K, Page C, Wali S, Cope D. Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin. Am J Emerg Med. 2005;23(3):415‐417.

http://doi.org/10.1016/j.ajem.2005.02.036

Cole RP. Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. Arch Intern Med. 2009;169(15):1439‐1441.

http://doi.org/10.1001/archinternmed.2009.221

Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157‐198.

http://doi.org/10.1006/frne.1999.0183

Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52(5):605‐611.

http://doi.org/10.1507/endocrj.52.605

Ewald N, Kloer HU. Severe hypertriglyceridemia: an indication for apheresis? Atheroscler Suppl. 2009;10(5):49‐52. http://doi.org/10.1016/S1567-5688(09)71810-0

Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher. 2003;18(4):181‐185. http://doi.org/10.1002/jca.10063

Syed H, Bilusic M, Rhondla C, Tavaria A. Plasmapheresis in the treatment of hypertriglyceridemia-induced pancreatitis: A community hospital’s experience. J Clin Apher. 2010;25(4):229‐234.

http://doi.org/10.1002/jca.20232

Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresis. J Clin Apher. 2007;22(3):106‐175.

https://doi.org/10.1002/jca.20129

Seda G, Meyer JM, Amundson DE, Daheshia M. Plasmapheresis in the management of severe hypertriglyceridemia. Crit Care Nurse. 2013;33(4):18‐24.

http://doi.org/10.4037/ccn2013346

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849‐1861.

http://doi.org/10.1016/S0140-6736(05)67667-2

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583‐1592. http://doi.org/10.1056/NEJMoa011090

Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287(14):1815‐1821.

http://doi.org/10.1001/jama.287.14.1815

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447‐455.

https://doi.org/10.1016/S0140-6736(99)07072-5

Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104(4):984‐991. http://doi.org/10.1038/ajg.2009.27

Tabla 1. Paraclínicos de ingreso
Publicado
2020-07-03
Cómo citar
Rincón Sánchez, R. A. M., Montaño-Padilla, G. S., Concha Mejía, A., & Rodríguez Ruíz, K. D. (2020). Utilidad de la plasmaféresis en la pancreatitis aguda por hipertrigliceridemia: A propósito de un caso. Revista Colombiana De Gastroenterología, 35(2), 226-231. https://doi.org/10.22516/25007440.350
Sección
Reporte de Casos